In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you preferentially use another PIK3 inhibitor or switch to T-DXd?

In a patient with PI3Km HR+ HER2-low breast cancer who is intolerant to capivasertib, what treatment would you switch to?

• Alpelisib + fulvestrant
• Inavolisib + fulvestrant
• Inavolisib + palbociclib + fulvestrant
• Trastuzumab-deruxtecan
• Alternative CDK4/6i + ET
• None of the above (please specify what you would likely use instead)
• Other